On July 4, 2023 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reported that the United States Patent and Trademark Office has granted a new patent protecting Tedopi, a therapeutic cancer vaccine treating HLA-A2 positive patients after secondary resistance to PD-1/PD-L1 immune checkpoint inhibitor treatment (Press release, OSE Immunotherapeutics, JUL 4, 2023, View Source [SID1234633043]). The new patent further improves the unique value proposition of Tedopi and provides protection until year 2037 in the US.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This US patent recognises the innovation of a multiepitope combination (all peptides included in Tedopi) administered after failure to PD-1/PD-L1 immune checkpoint inhibitor in HLA-A2 positive non-small cell lung cancer (NSCLC) patients. This further protection for Tedopi, OSE Immunotherapeutics’ most advanced late-stage asset, adds significant value to the Company’s product portfolio.

Nicolas Poirier, CEO of OSE Immunotherapeutics, said: "We are very pleased to expand our patent portfolio internationally with this new US patent strengthening the protection rights for Tedopi in the significant US market. This patent represents an additional milestone in the product’s clinical development based on the first Phase 3 positive results in non-small cell lung cancer after checkpoint inhibitor escape in secondary resistance. These data show a significant overall survival benefit, an improved quality of life and a better safety profile versus chemotherapy. The next confirmatory Phase 3 trial under preparation in second line treatment will address the same high unmet medical need. Tedopi presents a differentiated mechanism of action activating tumor specific T cells after acquired resistance of immune checkpoint inhibitor."

This patent family, focused on the same targeted population, has been filed internationally in other territories and has already been granted previously in Japan.

This population in second line treatment after failure to PD-1/PD-L1 inhibitor treatment, targeted with Tedopi, is estimated to be up to 100,000 patients per year in 7 major markets across the US, Europe, China and Japan. This estimate is based on HLA-A2-positive patients accounting for about 45% of all NSCLC patients, as well as the large and growing use of anti-PD-1/PD-L1 therapies and their failure rate.